Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
Name (Synonyms) | Correlation | |
---|---|---|
drug855 | Control Test Wiki | 0.50 |
drug3197 | Sublingual Methylene blue Wiki | 0.50 |
drug1992 | Methylene Blue Wiki | 0.50 |
Name (Synonyms) | Correlation | |
---|---|---|
drug765 | Clinical Trial Matching Wiki | 0.50 |
drug2919 | SLEDD with a L-MOD Wiki | 0.50 |
drug859 | Control patients Wiki | 0.50 |
drug1673 | Intracorporeal left hemicolectomy anastomosis Wiki | 0.50 |
drug3042 | Shared Decision Making Wiki | 0.50 |
drug1231 | Extracorporeal left hemicolectomy anastomosis Wiki | 0.50 |
drug857 | Control group Wiki | 0.29 |
drug610 | COVID-19 convalescent plasma Wiki | 0.22 |
Name (Synonyms) | Correlation | |
---|---|---|
D016889 | Endometrial Neoplasms NIH | 0.50 |
D004938 | Esophageal Neoplasms NIH | 0.50 |
D013274 | Stomach Neoplasms NIH | 0.50 |
Name (Synonyms) | Correlation | |
---|---|---|
D012878 | Skin Neoplasms NIH | 0.50 |
D009423 | Nervous System Neoplasms NIH | 0.50 |
D007680 | Kidney Neoplasms NIH | 0.50 |
D016543 | Central Nervous System Neoplasms NIH | 0.50 |
D005909 | Glioblastoma NIH | 0.50 |
D008113 | Liver Neoplasms NIH | 0.50 |
D007822 | Laryngeal Neoplasms NIH | 0.50 |
D013736 | Testicular Neoplasms NIH | 0.50 |
D002292 | Carcinoma, Renal Cell NIH | 0.35 |
D002583 | Uterine Cervical Neoplasms NIH | 0.35 |
D012004 | Rectal Neoplasms NIH | 0.35 |
D018281 | Cholangiocarcinoma NIH | 0.35 |
D018358 | Neuroendocrine Tumors NIH | 0.35 |
D010190 | Pancreatic Neoplasms NIH | 0.29 |
D006258 | Head and Neck Neoplasms NIH | 0.29 |
D002277 | Carcinoma NIH | 0.25 |
D001943 | Breast Neoplasms NIH | 0.22 |
D008175 | Lung Neoplasms NIH | 0.20 |
Name (Synonyms) | Correlation | |
---|---|---|
HP:0003003 | Colon cancer HPO | 1.00 |
HP:0002896 | Neoplasm of the liver HPO | 0.50 |
HP:0008069 | Neoplasm of the skin HPO | 0.50 |
Name (Synonyms) | Correlation | |
---|---|---|
HP:0012114 | Endometrial carcinoma HPO | 0.50 |
HP:0100006 | Neoplasm of the central nervous system HPO | 0.50 |
HP:0010788 | Testicular neoplasm HPO | 0.50 |
HP:0009726 | Renal neoplasm HPO | 0.50 |
HP:0012174 | Glioblastoma multiforme HPO | 0.50 |
HP:0100751 | Esophageal neoplasm HPO | 0.50 |
HP:0004375 | Neoplasm of the nervous system HPO | 0.50 |
HP:0006753 | Neoplasm of the stomach HPO | 0.50 |
HP:0100605 | Neoplasm of the larynx HPO | 0.50 |
HP:0005584 | Renal cell carcinoma HPO | 0.35 |
HP:0100634 | Neuroendocrine neoplasm HPO | 0.35 |
HP:0100743 | Neoplasm of the rectum HPO | 0.35 |
HP:0030153 | Cholangiocarcinoma HPO | 0.35 |
HP:0030079 | Cervix cancer HPO | 0.35 |
HP:0002894 | Neoplasm of the pancreas HPO | 0.29 |
HP:0012288 | Neoplasm of head and neck HPO | 0.29 |
HP:0030731 | Carcinoma HPO | 0.25 |
HP:0003002 | Breast carcinoma HPO | 0.22 |
HP:0100526 | Neoplasm of the lung HPO | 0.20 |
Navigate: Correlations HPO
There are 4 clinical trials
International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinical impact on pts with advanced cancer to facilitate clinical trial enrollment (CTE), as well as the financial impact, and potential outcomes of the intervention.
Description: CTE Accrual
Measure: Proportion of patients Eligible for CTE versus Actual CTE Time: Through study completion, an average of 1 yearDescription: OS
Measure: Impact of CTE on Overall Survival (OS), estimated by Kaplan-Meier and Cox multivariable survival analysis Time: 4 yearsDescription: PFS
Measure: Impact of CTE on Progression-Free Survival (PFS), estimated by Kaplan-Meier and Cox multivariable survival analysis Time: 4 yearsDescription: To identify barriers to accruals to clinical trials, as measured and reported by a questionnaire
Measure: Identification of Barriers to CTE Time: Through study completion, an average of 1 yearDescription: To Analyze Individual Standard of Care Chemotherapy Utilization (nominal), across treatment lines (numeric); data will be combined and aggregated to report chemotherapy utilization rate (%).
Measure: Real World Data Analytics Time: Through study completion, an average of 1 yearDescription: VTB Use Rate
Measure: Virtual Tumor Board Utilization Time: Through study completion, an average of 1 yearDescription: Time to CTE
Measure: Time from Intervention to Actual CTE (months) Time: Through study completion, an average of 1 yearThe study is a cross-sectional survey study targeting patients aged 45-75 who had their screening or surveillance colonoscopy postponed or delayed due to the COVID pandemic. Study staff will survey a random subsample of patients to assess anxiety, COVID risk tolerance, cancer worry, willingness to screen and barriers to screening colonoscopy, and preference for colonoscopy and alternative colon cancer screening options. Eligible patients will be sent a survey packet in the mail that will include a cover letter, an information sheet describing the study, an incentive, and the survey. The cover letter will include information for participants to opt-out if they desire. Patients will be asked to complete the survey and return it back to study staff. Consent is implied with return of the survey. For the study, staff plan to invite 300 patients and expect to receive 195 completed surveys. Analyses will examine whether COVID-19 has changed patients' interest in colon cancer screening and the strength of patients' preferences for colonoscopy and other approaches to colon cancer screening. It will then examine factors associated with positive and negative views on rescheduling colonoscopies such as anxiety, worry, and risk perceptions.
Description: Item with 5-point response assessing whether COVID-19 has increased, decreased or not changed interest in colon cancer screening
Measure: Interest in colon cancer screening Time: at start of study--between one week and 2 months after start of studyDescription: Item with 5-point response (definitely want to definitely do not want) measuring interest in having a stool test for colon cancer
Measure: Preference for stool testing Time: at start of study--between one week and 2 months after start of studyDescription: Item with 5-point response (definitely want to definitely do not want) measuring interest in postponing colonoscopy for one year
Measure: Preference for postponing colonoscopy for one year Time: at start of study--between one week and 2 months after start of studyDescription: Item with 5 point response (extremely worried to not at all worried) assessing worry about the delay of the colonoscopy on their colon cancer risk
Measure: Worry about delay Time: at start of study--between one week and 2 months after start of studyDescription: Item with 5-point response (very high to very low) assessing patients' perception about risk of getting COVID-19 from having a colonoscopy
Measure: Risk perception on COVID-19 Time: at start of study--between one week and 2 months after start of studyOBJECTIVE: The aim of the study is to demonstrate that the intracorporeal resection and anastomosis in left-sided colon cancer, sigma and upper rectum, is not inferior to extracoprporeal resection and anastomosis, in terms of anastomotic leakage. BACKGROUND: Due to the recent events of a pandemic respiratory disease secondary to infection by SARS-CoV-2 virus or coronavirus 19 (COVID19), surgeons have been forced to adapt our surgical procedures in order to minimize exposure to the virus as much as possible. Based on the recommendations in case of surgery in patients with highly contagious viral diseases, the latest studies suggest minimally invasive accesses to minimize the risk of contagion. One of the proposed measures is the performance of intracorporeal anastomoses. Therefore, given the extensive experience of our center in minimally invasive surgery and studies on the validation of intracorporeal anastomosis techniques in both laparoscopic surgery of the right colon and rectum (TaTME), and the study of advantages that they can provide to the patient, our intention is to apply it to surgery on the left colon, sigma and upper rectum. Our hypothesis is that exteriorization of the colon through an accessory incision increases the risk of tension at the mesocolon level, thus increasing the risk of vascular deficit at the level of the staple area and it may increase the rate of anastomotic leakage. In this sense, studies that validate a standard technique of intracorporeal anastomosis in left colon surgery and that demonstrate its benefit with respect to extracorporeal anastomosis are lacking. We intend to describe a new intracorporeal anastomosis technique (ICA) that is feasible and safe for the patient and that can be applied universally. Once the ICA technique is established, it will allow us to determine its non-inferiority compared to the standard technique performed up to now with extracorporeal anastomosis. METHODS: All consecutive patients with left-sided, sigma and upper rectum adenocarcinoma will be included into a prospective cohort and treated by laparoscopy with totally intracorporeal resection and anastomosis. They will be compared with a retrospective cohort of consecutive patients of identical characteristics treated by laparoscopy with extracorporeal resection and anastomosis, in the immediate chronological period.
Description: Percentage of anastomic leak (defined in accordance with Peel et al.).
Measure: Percentage of anastomotic leak (AL) Time: 30 daysDescription: Dindo-Clavien Classification
Measure: Rate of global morbidity Time: 30 daysDescription: SSI in accordance with the Center for Disease Control (CDC) National
Measure: Rate of Surgical site infection Time: 30 daysDescription: Percentage of re-interventions due to surgical complications
Measure: Rate of Re-interventions Time: 30 daysThe goal of the study is to examine whether a shared decision making intervention improves decision making about colon cancer screening for patients who had their colonoscopy delayed or postponed due to the COVID pandemic. Eligible patients (n=800) will be randomly assigned to either the intervention or control arm. A subset will be surveyed about 6 weeks post intervention to measure shared decision making, their intention to follow through with screening, and their decisional conflict. Study staff will conduct medical chart review to track receipt of colon cancer screening within 6 months. The statistician will test whether patients in the intervention arm report more shared decision making, less decisional conflict, higher intention to follow through on screening and have higher screening rates compared to those in the control arm.
Description: short patient reported scale asks patients about discussion of options, pros and cons of colonoscopy and discussion of patients' preferences. Total scores range from 0-4 with higher scores indicating higher shared decision making.
Measure: Shared Decision Making (SDM) Process Scale Score Time: 6 weeks after interventionDescription: the 4-item version of the decisional conflict scale, total score ranges from 0-4 with greater scores indicating less decisional conflict.
Measure: Decisional Conflict (SURE scale) Time: 6 weeks after interventionDescription: One item will assess patients' preferred approach to screening (with responses of colonoscopy, stool card test, no screening, not sure).
Measure: Patient's preferred approach to screening Time: 6 weeks after interventionDescription: One item will assess patients' intention to follow through with their preferred approach on a 5-point scale from not at all likely to extremely likely.
Measure: Intention to screen Time: 6 weeks after interventionDescription: Percentage of patients who had completed colon cancer screening test
Measure: Colon cancer screening rate Time: 6 months after randomizationAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports